Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × tremelimumab × Dermatologic × Clear all

Phase

Status

Sponsor Class

OTHER 10 INDUSTRY 8 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Dermatologic 1

Conditions

Interventions

Nivolumab 5 Interleukin-2 4 pembrolizumab 3 Melphalan 3 Ipilimumab 3 apatinib 2 tremelimumab 1 tislelizumab 1 fludarabine 1 entinostat 1 encorafenib 1 camrelizumab 1 binimetinib 1 Tramadol 1 Surgical Procedures, Operative 1 Physical Examination 1 Mohs Surgery 1 Microscopy, Confocal 1 Methotrexate 1 Metastasectomy 1 Immunotherapy 1 Ibuprofen 1 FMT protocol 1 Dermoscopy 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05928962 2023-07-10

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Fujian Cancer Hospital

Phase 1 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡